Description

• CANOTRIA™ 2 % CREAM may assist in the treatment of uraemic pruritus in haemodialysis patients who need alternatives to steroid based therapies.
• CANOTRIA™ 2 % CREAM may assist in the suppression of skin inflammation in psoriasis, when standard therapies have been ineffective.
• CANOTRIA™ 2 % CREAM may also be effective as adjunct therapy for the management of pain associated with epidermolysis bullosa in cases where patients are already on the highest tolerated dose of opioid therapy and still experience background pain.

SKIN CONDITIONS WHERE CANOTRIA™ MAY BE OF BENEFIT

ACNE¹

• Acne is a chronic inflammatory disorder of pilosebaceous units (hair follicles and their accompanying sebaceous gland) of the skin.
• Acne is considered a chronic disease with up to 50% of cases persisting into adulthood.
• The pathogenesis of acne is multifactorial. The most notable factors that influence its development are:
  • Hyperkeratinisation (a disorder of the cells lining the inside of a hair follicle)
  • increased sebum production
  • bacterial colonization of the follicle and inflammation.
• Inflammation localized to the pilosebaceous unit can be considered the defining feature of acne and should be addressed via multiple therapeutic pathways.
• Treatment should target as many factors as possible in order to prevent the formation of microcomedones (blackheads and whiteheads are the most common forms of comedonal acne) and prevent scarring and post-inflammatory hyperpigmentation.
• Topical treatments are widely considered to be a mainstay of care because they effectively target the pathogenic factors and address the other key considerations of acne.

PRURITUS²

• Pruritus, or itch, is a common sensation that causes a person to want to scratch.
• Pruritus is a complex process that involves the stimulation of free nerve endings found superficially in the skin.
• The sensation of pruritus is transmitted through the C-fibres in the skin to the dorsal horn of the spinal cord, and then, via the spinothalamic tract to the cerebral cortex for processing.
• Symptomatic treatment can be used in addition to treating the underlying disease process in order to provide earlier relief of the ‘itch’.

ECZEMA³

• Eczema is a chronic, pruritic, inflammatory skin disease with wide ranging severity.
• The causes of eczema are not completely understood, but dysfunction of the skin barrier, likely the result of both genetic and environmental factors, and immune dysregulation are important in its pathophysiology.
• The goals of treatment are to stop the itch-scratch cycle, maintain skin hydration, and avoid or minimize factors that can trigger or aggravate eczema.